<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530672</url>
  </required_header>
  <id_info>
    <org_study_id>HS647</org_study_id>
    <nct_id>NCT01530672</nct_id>
  </id_info>
  <brief_title>Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test</brief_title>
  <acronym>MBIO</acronym>
  <official_title>Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a diagnostic validation study for a combined Syphilis/HIV test made by MBio&#xD;
      Diagnostics, Inc (MBio, Boulder, CO, USA). Although the MBio Syphilis/HIV diagnostic platform&#xD;
      is designed for use at point of care (POC), it is made to provide similar performance as&#xD;
      reference standards. Diagnosing HIV and syphilis accurately with a single POC test will save&#xD;
      time for clinic health workers and technicians, reduce loss-to follow-up caused by lengthy&#xD;
      delays for lab-based tests, and save costs by eliminating the need for multiple tests. For&#xD;
      this study, the sensitivity and specificity of the MBio HIV/Syphilis Serology System&#xD;
      point-of-care diagnostic test will be determined using reference tests performed under&#xD;
      controlled laboratory conditions. For this, clients receiving routine care in the ANCs at the&#xD;
      New Nyanza Provincial General Hospital (NNPGH) and Kisumu District Hospital (KDH) will be&#xD;
      consented to provide blood for the proposed study. Study volunteers will receive HIV and&#xD;
      syphilis rapid tests provided as part of routine care, and will donate an additional blood&#xD;
      for evaluating the MBio test against the reference tests in a laboratory setting. This study&#xD;
      is an investigational prototype, not for product registration. The results from this study&#xD;
      will be used to inform product development of a second iteration of the MBio device design.&#xD;
      At the time that the device is ready to be registered, it will undergo another field&#xD;
      evaluation at which time it will be submitted to the appropriate regulatory body. Because the&#xD;
      MBIO device is an HIV test, the device would be submitted to National AIDS &amp; STI Control&#xD;
      Program (NASCOP), which is the appropriate regulatory body for HIV tests in Kenya.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device sensitivity/specificity</measure>
    <time_frame>same-day</time_frame>
    <description>Sensitivity &amp; specificity of the MBIO device against HIV and syphilis reference tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent agreement with clinical diagnosis</measure>
    <time_frame>same-day</time_frame>
    <description>Percent agreement with HIV &amp; syphilis rapid tests completed at clinic</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2900</enrollment>
  <condition>HIV</condition>
  <condition>Syphilis</condition>
  <arm_group>
    <arm_group_label>ANC clients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MBIO POC combined HIV syphilis test ( SnapEsi)</intervention_name>
    <description>Venipuncture for routine ANC screening plus additional for device validation purposes.</description>
    <arm_group_label>ANC clients</arm_group_label>
    <other_name>MBIO</other_name>
    <other_name>SnapEsi-beta HIV-1/Syphilis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Attending her first routine ANC visit and willing to undergo tests for HIV/syphilis&#xD;
&#xD;
          -  Able and willing to legally consent for enrollment&#xD;
&#xD;
          -  Able to demonstrate-comprehension of study details as they are explained in the&#xD;
             consent process by passing all the test questions of understanding. The subject is&#xD;
             only allowed two attempts at passing the test of understanding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to provide written informed consent.&#xD;
&#xD;
          -  Unable to legally consent (minor without guardian)&#xD;
&#xD;
          -  Opt out of HIV or syphilis test&#xD;
&#xD;
          -  Previously diagnosed with autoimmune disorder (lupus, Lyme disease), as determined by&#xD;
             client recollection or clinical record.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Steele, Ph.D, M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PATH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Waitumbi, Ph.D, D.V.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Project</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen Tietje, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PATH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kisumu District Hospital</name>
      <address>
        <city>Kisumu</city>
        <state>Nyanza</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Nyanza Provincial General Hospital</name>
      <address>
        <city>Kisumu</city>
        <state>Nyanza</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <link>
    <url>http://www.mbiodx.com/technology/</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>January 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Syphilis</keyword>
  <keyword>Combination</keyword>
  <keyword>POC</keyword>
  <keyword>point-of-care</keyword>
  <keyword>MBIO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

